Ask AI
ProCE Banner Activity

TROPION-Breast02: PFS2 and Additional Efficacy Outcomes With 1L Dato-DXd vs Chemotherapy in Advanced TNBC

Conference Coverage
Slideset

In this analysis of secondary efficacy outcomes from the phase III TROPION-Breast02 trial, PFS2 and time to first and second subsequent therapies show consistent benefit with Dato-DXd vs chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitors.

Released: June 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and Stemline Therapeutics, Inc.

Lilly

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from breast cancer studies at ASCO 2026 and expert guidance to optimize personalized breast cancer care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify breast cancer patients most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for breast cancer to accelerate their effective incorporation into clinical practice